Heart defects caused by loss-of-function mutations in CHD7 are a frequent cause of morbidity and mortality in CHARGE syndrome. Here we review the clinical and molecular aspects of CHD7 that are related to the cardiovascular manifestations of the syndrome. The types of heart defects found in patients with CHD7 mutations are variable, with an overrepresentation of atrioventricular septal defect and outflow tract defect including aortic arch anomalies compared to nonsyndromic heart defects. Chd7 haploinsufficiency in mouse is a good model for studying the heart effects seen in CHARGE syndrome, and mouse models reveal a role for Chd7 in multiple lineages during heart development. Formation of the great vessels requires Chd7 expression in the pharyngeal surface ectoderm, and this expression likely has an non-autonomous effect on neural crest cells. In the cardiogenic mesoderm, Chd7 is required for atrioventricular cushion development and septation of the outflow tract. Emerging knowledge about the function of CHD7 in the heart indicates that it may act in concert with transcription factors such as TBX1 and SMADs to regulate genes such as p53 and the cardiac transcription factor NKX2.5.
outflow tract and septal defects being most prevalent. As shown in Figure 1 , an overrepresentation of AVSD, PDA and outflow tract defects was seen in patients with a CHD7 mutation as compared to a group of non-syndromic heart malformations (Corsten-Janssen et al., 2013) . Aortic arch anomalies were also frequently present in the cohort, including abnormal branching such as aberrant subclavian artery (Corsten-Janssen, van Ravenswaaij-Arts, & Kapusta, 2016) .
| CHD7 MUTATIONS IN COHORTS OF PATIENTS WITH HEART DEFECTS
Pathogenic CHD7 mutations may only cause a small subset of CHARGE manifestations in some individuals. For example, a pathogenic CHD7 mutation was identified during diagnostics in a girl who only expressed a typical external ear anomaly and a heart defect (Bergman et al., 2011) . CHD7 mutations have also been identified in the screening of cohorts with only hypogonadotropic hypogonadism and anosmia (Bergman et al., 2011) . While the phenotypes in these cases are limited, the identification of a CHD7 mutation is still important for counseling parents and patients on recurrence risk, prenatal options and the clinical follow up (Bergman et al., 2011) .
Since CHD7 causes congenital heart defects in most people harboring a pathogenic CHD7 mutation (Corsten-Janssen et al., 2013) , several studies have analyzed CHD7 in cohorts of patients with cardiovascular malformations and an overview of these studies is shown in Table 1 . Screening of only CHD7 in a cohort of 67 patients with isolated heart defects (Qi et al., 2008) and in a cohort of 46 patients selected for their type of heart defect and one other feature of CHARGE syndrome (Corsten-Janssen et al., 2014) identified no pathogenic mutations. These two studies indicate CHD7 mutations are not a major cause of congenital heart defects, even when patients are selected for extra-cardiac features. However, CHARGE syndrome had been diagnosed in around 1% of the patients in two larger retrospective clinical studies: one of 310 patients with the most common variation in aortic arch branching, bicarotid trunk (Oswal et al., 2014) , and the other of 257 patients with tetralogy of Fallot with pulmonary stenosis (Oswal et al., 2014; Reinshagen, Vodiskar, Muhler, Hovels-Gurich, & Vazquez-Jimenez, 2014) . Although the main intention of these studies was not to search for syndromes, their results suggest CHD7 mutations could be identified by screening in more extensive cohorts.
Next generation sequencing techniques have made it possible to screen multiple genes involved cardiac development, including CHD7.
An exome sequencing analysis of 362 parent-child trios in which the child had a severe congenital heart defect revealed a de novo truncating CHD7 mutation in one proband with syndromic tetralogy of Fallot (Zaidi et al., 2013) . Looking at this case retrospectively, the patient might have been eligible for CHD7 analysis based on the presence of extra-cardiac features (cleft lip and palate, inguinal hernia, micropenis, sensorineural hearing loss, abnormal neurological development) (Bergman et al., 2011) . In a cohort of 81 patients with AVSD, an enrichment of rare and rare potentially damaging CHD7 mutations was identified while screening 112 AVSD-related genes. These patients had syndromic as well as non-syndromic heart defects, and the authors suspected that the CHD7 variants contributed to the AVSD, but the pathogenic effect of the rare CHD7 variants they identified in this study has not been proven (D'Alessandro et al., 2016) .
Currently, direct analysis of CHD7 only seems warranted when a congenital heart defect is present in conjunction with at least one other FIGURE 1 Types of heart defects caused by CHD7 mutations. Distribution of congenital heart defects in 202 patients with a CHD7 mutation (a) and in 1,007 patients with non-syndromic congenital heart defects (b). The combination of AVSD, outflow tract defects and PDA encompasses about 52% of the heart defects in the CHD7 mutation group but these defects represent only 12% in the non-syndromic group. Figure adapted from (Corsten-Janssen et al., 2013) . AVSD, atrioventricular septal defects; LVOTO, left ventricular outflow tract obstruction; OFT, outflow tract defects; PDA, patent ductus arteriosus; RVOTO, right ventricular outflow tract obstruction major CHARGE feature. However, our recommendation based on the current evidence is that CHD7 should be added to gene panels for heart defect, especially those for syndromic heart defects.
| REVIEW OF HEART DEVELOPMENT
Before considering how CHD7 orchestrates the complex events that take place during cardiac morphogenesis, it is useful to review the relevant developmental biology (for further review see Epstein (2010) ).
The heart is the first organ required for embryonic survival. The main cellular contribution to cardiac structures is provided by mesodermal derivatives, although the other germ layers (ectoderm and endoderm) also have a vital role to play. The cardiac mesoderm cells are located in the cardiac crescent and the two arms of the crescent migrate medially to form the primitive heart tube. The heart chambers then form via a process of "ballooning" out from this tube. The cardiac mesoderm itself contains two groups of cells generally thought to comprise distinct cel lineages that give rise to specific regions of the heart. The left ventricle and parts of the atria are derived from the so called first heart field. The right ventricle, much of the outflow tract, parts of the atria and atrial septum are derived from second heart field cells that migrate to the poles of the early heart tube. Thus, second heart field cells are added after the first heart field contribution.
Complex morphogenetic events are required to establish the fourchambered heart. The heart undergoes looping such that the left and right atria become aligned with their respective ventricles. In addition, the outflow tract, which is the single artery emanating from the heart, septates into the pulmonary artery and aorta. The region between the atria and ventricles forms swellings called cushions that are composed of a jelly-like substance. The endothelial lining over the cushions undergoes an endothelial to mesenchymal transition with the resulting cells migrating into the cushions, and the cushions are then remodeled to form the atrioventricular valves. An analogous process is required in the outflow tract to create the aortic and pulmonary valves and to form an effective septum between these two vessels. Notably, the septation of the ventricles and outflow tract is dependent upon a normal contribution from an additional group of neuroectodermally derived cells called the cardiac neural crest lineage (cNCC). Because CHD7 is expressed in all germ layers and the neural crest during heart development, it has the potential to influence many relevant events. The relationship between these various cell lineages and the subsequent heart structures and pathways that are all impacted by loss of CHD7 activity is presented schematically in Figure 2 .
As we will discuss below, analysis of mouse (and other animal) models has shed light upon some of these processes.
| CHD7 MOUSE HAPLOINSUFFICIENCY MODELS AND THE HEART
Chemical mutagenesis has yielded a number of mutations in Chd7, several of which were studied prior to the identification of the underlying genetic etiology of CHARGE syndrome (Alavizadeh et al., 2001; Bosman et al., 2005) . These mice were identified through circling or other behavioral phenotypes linked to inner ear abnormalities. More recently, "gene trap" mutants have been studied in which the coding region of Chd7 is replaced by a reporter gene that provides a read out of Chd7 expression in these animals (Hurd et al., 2007; Randall et al., 2009 ). These mouse models recapitulate well the cardiac phenotype seen in the human syndrome, with ventriculoseptal defects, atrial septal defects and interruption of the aortic arch type B reported.
However, Chd7 null mice die at mid gestation and have severe growth delay, so work on these mice has been limited.
| CHD7 AND THE p53 PATHWAY
During their analysis of mice containing one wild type and one transcriptionally dead mutant variant of the tumor-suppressor Moreover, when Chd7 mutants were bred to give homozygous null Chd7 embryos in the context of a single p53 loss-of-function allele, the Chd7 null phenotype was partially rescued, which suggests a role for p53 downstream of CHD7. However, while the rescue did not permit normal heart development, it appeared to allow a further 24 hr of development compared to Chd7 nulls. This effect may be relatively non-specific, occurring via inhibition of apoptosis in null embryos by heterozygosity for p53. It is worth noting that CHD7
regulates rRNA biosynthesis via the Treacle protein mutated in
Treacher Collins syndrome (Zentner et al., 2010) and that Tcof1 mutants can be similarly rescued by crossing to heterozygous p53
loss-of-function mice (Jones et al., 2008) . In general, the growth retardation and developmental delay in constitutive Chd7 null mutants makes it difficult to disentangle cause from effect when considering the poor heart morphogenesis seen in these mutants. (Liu et al., 2014) . Of interest, this complex was found to regulate NKX2.5, an important transcription factor expressed in both heart fields and required for heart development. NKX2.5 demonstrates haploinsufficiency in humans, with mutations being associated with arrhythmia and atrial septal defect. This suggests other pathogenic variants in genes that are regulated by complexes in which CHD7 is involved may contribute to sporadic congenital heart defects as well.
| TISSUE SPECIFIC REQUIREMENTS FOR CHD7
It is clear from work conducted in human embryonic stem cells and mouse embryos that CHD7 plays a major role in NCC development. In FIGURE 2 Pathways and lineages in which CHD7 is active during heart development3. Diagram presents a schematic of the heart and proximal vessels at around E10.5 of mouse gestation and 4-5 weeks in human gestation. The different lineages described in the review are color coded as indicated. Structures may comprise more than one lineage, for example, mesoderm and neural crest in the PAAs, OFT, and semilunar valves. Groups of cells or lineages are underlined: NCC, neural crest cells; FHF, first heart field; SHF, second heart field. The approximate anatomical location of their contribution is indicated by the curved arrows. Thus the NCC contribute to the smooth muscle of the PAAs, SHF mesoderm to the endothelial lining, and both lineages contribute to the outflow tract. The official names of the genes/protein/ pathways implicated in the process are given. Non-italicized names represent protein interactors of CHD7. Italicized names are genes or gene families that are directly and/or indirectly regulated by CHD7. Autonomous/non-autonomous indicates where the effect occurs within a specific cell lineage or where cell-cell signaling processes are involved human embryonic stem cells, CHD7 is complexed with another chromatin remodeling protein called PBAF (polybromo-and Brg1/ Brahma-associated factor). Together they act at the enhancer of the SOX9 transcription factor gene, which is itself a key component of the NCC gene regulator network (Bajpai et al., 2010) . CHD7 also partners with BRG1 to regulate the SEMA3-family receptor PlexinA2 that is required for outflow tract formation (Li et al., 2013) . Indeed, Sema3c, the specific Sema3 involved in this process, is down-regulated in Chd7 null embryos (Schulz et al., 2014) . However, NCCs secrete Sema3c, and SEMA3 signaling to NCCs is not required for cardiac outflow tract septation (Plein et al., 2015) , so additional mechanisms or lineages must be involved (see mesoderm, below).
As we discussed above, there is substantial evidence from in vitro work that CHD7 is involved in NCC development. In fish, NCC migration, fate choice and differentiation are all affected in chd7 morphants (Balow et al., 2013; Patten et al., 2012) , although this observation comes with the caveat that NCCs seem particularly susceptible to off-target morpholino effects (Boer, Jette, & Stewart, 2016) . It is therefore surprising that, while NCC-specific knockout of
Chd7 results in craniofacial abnormalities, cardiac defects were not reported (Sperry et al., 2014) . This agrees with the genetic rescue experiments of Randall et al. (2009) . In this paradigm, embryos heterozygous for Chd7 following a gene trap can be induced, via Cre recombinase expression, to re-express Chd7 from the trapped allele in specific tissues. Thus, Cre-containing embryos will be dizygous in the targeted tissue and heterozygous in all others. Rescue of Chd7 expression in NCCs using Wnt1Cre failed to correct abnormalities of the pharyngeal arch arteries (PAAs). On the other hand, the Ap2αCre driver, which rescues expression in the pharyngeal surface ectodermal (PSE) layer of the embryo as well as in NCCs, does rescue these phenotypes. This implies that there is a non-autonomous role for CHD7 in the PSE whereby it controls the signaling required for the NCC to make its contribution to cardiovascular development. This is reminiscent of tissue-specific requirements for the TBX1 transcription factor (Calmont et al., 2009 ), an issue we will revisit below.
The role of CHD7 in cardiac progenitors was analyzed using a Mesp1Cre driver. Mesp1 is expressed in the common progenitor cells of both the first and second heart field, together with cells of the craniofacial mesoderm that will form skeletal muscle of the head and neck (Diogo et al., 2015) . In addition to their role in the creation of cardiomyocytes, Mesp1 lineage cells can give rise to endothelial, smooth muscle and mesenchymal cells (such as fibroblasts). Embryos null for Chd7 in the Mesp1Cre lineage bypassed the early lethality noted in the constitutive nulls but died starting from E14.5 to birth (Payne et al., 2015) . Surface hemorrhage was observed in embryos surviving to E15.5, a sign of possible heart failure or defective vessel development. A range of cardiovascular defects were present in these embryos. Presence of interruption of the aortic arch type B and aberrant subclavian artery reflected abnormal growth and remodeling of the PAA system. Severe intracardiac defects were also observed that recapitulated, to varying extents, a rare human heart malformation called the Holmes heart. Late gestation hearts were observed to have both a double inlet left ventricle (with small right ventricle) and a double outlet right ventricle with a single atrioventricular valve. There was also an occasional instance of common arterial trunk. These phenotypes likely reflected an earlier function of CHD7 since the protein itself was not detectable in hearts of E13.5 embryos. Analysis of the transcriptome of Mesp1Cre-Chd7 conditionally mutant hearts at E11.5 and E12.5 identified several dysregulated pathways, including down-regulation of Sema3c in both the second heart field and ingressing NCCs. Knockout of Chd7 specifically in the endothelial cell lineage did not show any evidence of vessel defect, indicating that the surface hemorrhage and edema may be due to heart failure, and this is supported by the observation of altered expression of several genes encoding proteins involved in excitation-contraction coupling. Indeed, cultured cardiomyocytes from Mesp1Cre-Chd7 conditional hearts displayed aberrant calcium currents, suggesting that cardiomyocyte function is disturbed in these mutants (Payne et al., 2015) .
| CLINICAL AND MOLECULAR OVERLAP OF CHARGE SYNDROME WITH OTHER HEART DEFECT SYNDROMES
An overlap between the cardiac defects seen in CHARGE syndrome and those seen 22q11.2 deletion syndrome (MIM192430 and 188400) was first noted by Lin et al. in 1987 (Lin et al., 1987 . Many studies have since focused on the overlap in the phenotypes of these two syndromes, which includes heart defects, cleft palate, developmental delay, renal abnormalities, and hearing loss (Corsten-Janssen et al., 2012; Jyonouchi et al., 2009) . With respect to heart defects, it is outflow tract abnormalities, particularly aortic arch anomalies, that occur in both syndromes. Further, CHD7 mutations have been identified in patients with a 22q11.2 deletion phenotype and, vice versa, 22q11.2 deletions have been identified in patients suspected of having CHARGE syndrome (Corsten-Janssen et al., 2012; Randall et al., 2009; Sanka, Tangsinmankong, Loscalzo, Sleasman, & Dorsey, 2007) . The aplasia or hypoplasia of the 4th PAA mentioned earlier in the context of Chd7 haploinsufficiency is a frequent finding in Tbx1 heterozygous embryos (Randall et al., 2009 ).
Like Chd7, expression of Tbx1 in the PSE is required for PAA formation.
Moreover, embryos doubly heterozygous for both Chd7 and Tbx1 have more frequent and more severe great vessel defects, suggesting that these two transcriptional regulators operate in the same developmental pathway (Randall et al., 2009 ). This may relate to their effects on chromatin: TBX1 is known to recruit histone methylases to chromatin, TBX1 chromatin binding is associated with H3K4me1 modification (Fulcoli et al., 2016) , and CHD7 chromatin binding peaks coincide with peaks of H3K4me1 (Schnetz et al., 2009 . One possible scenario for this connection is that TBX1 establishes a chromatin modification that is interpreted by CHD7, and CHD7 then remodels the nucleosomes at these sites.
As shown in (Continues) Schulz et al., 2014; Verhagen, Oostdijk, Terwisscha van Scheltinga, Schalij-Delfos, & van Bever, 2014) . This is interesting given that KMT2D and CHD7 have a molecular link through interactions with the same chromatin machinery (members of the WAR complex) (Schulz et al., 2014) and they both share gene targets (Butcher et al., 2017) . Exome sequencing of patients with sporadic congenital heart defects revealed a relative excess of mutations in genes encoding similar chromatin modifiers, particularly those that regulate methylation at lysine 4 of histone H3, pointing to the importance of these proteins in normal cardiovascular development (Zaidi et al., 2013) . As chromatin methylation (and other modifications) may be influenced by environmental factors, for instance via homocysteine and the onecarbon cycle, they may be nodes for gene-environment interactions (Selhub, 2002) .
| CONCLUSIONS
The cardiac phenotype in patients with a CHD7 mutation is variable, but there is a relative over-representation of AVSD and outflow tract defects including aortic arch anomalies. Chd7 deficient mice have a cardiac phenotype that overlaps with that of human CHARGE patients. Molecular studies have elucidated some underlying mechanisms and genetic interactions during cardiac development that give rise to congenital heart defect in patients with CHD7
mutations and overlapping heart syndromes. Chd7 has a role in several cell lineages, for example in the PSE for remodeling of the pharyngeal arch arteries and in the mesoderm for atrioventricular cushion development and septation of the outflow tract. CHD7
protein likely interacts with other gene-regulators such as TBX1 and SMADs to regulate genes as the cardiac transcription factor NKX2.5.
Rare variants in these genes may contribute to the genetic architecture of sporadic congenital heart defects. Clinical information is on genetic heart syndromes that have clinical overlap with CHARGE syndrome. Most of the genes in this table also have a molecular link with CHD7. SOX2 and CHD7 have been shown to physically interact with JAG1 and GLI3 as target genes (Engelen et al., 2011) . CHD7 and KMTD2 interact with members of the same chromatin remodeling machine and have common target genes (Butcher et al., 2017; Schulz et al., 2014; Verhagen et al., 2014) . TBX1 and CHD7 are both needed for normal PAA development, and CHD7 alters the expression of TBX1 in inner ear neurogenesis (Hurd, Poucher, Cheng, Raphael, & Martin, 2010; Randall et al., 2009) . For EFTUD2 and ZEB2, only clinical overlap has been described so far (Luquetti et al., 2013; Wenger et al., 2014) . ASD, atrial septal defects; AVSD, atrioventricular septal defect; Coa, coarctation of aorta; OFT, outflow tract anomalies; PDA, patent ductus arteriosus; PPS, Peripheral pulmonary artery stenosis; PS, Pulmonary artery stenosis; SCC, semicircular canals; TOF, tetralogy of Fallot; VSD, ventricular septal defect.
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